|
For-profit dialysis centers continued to use anemia drug after black box warning
MedCity News It’s just that it does have side effects and people do need to be aware of them,” said Dr. Nina Tolkoff-Rubin, director of renal transplantation and hemodialysis at Massachusetts General Hospital in Boston. Previous studies had found that for-profit … |
Documentary examines lives of bullied children – Brantford Expositor
Documentary examines lives of bullied childrenBrantford ExpositorFinding work as a rickshaw driver he meets Max Lowe, a doctor from Miami who lives in India, avoiding the past. Together with an Irish nurse, a Polish priest and Mother Teresa, they start…
Blood Donation camp held – Rising Kashmir – Rising Kashmir (press release)
Blood Donation camp held – Rising KashmirRising Kashmir (press release)Srinagar, May 15: As part of its social responsibility Department of Students Welfare (DSW) University of Kashmir in collaboration with the Department of Hematology and Transfusion …
Scientists Find New Gene Markers for Cancer Risk – Indiawest.com – India West
Scientists Find New Gene Markers for Cancer Risk – Indiawest.comIndia WestProstate cancer is the second most common cancer in men after lung cancer, with about 900,000 new cases every year. Ovarian cancer accounts for about four percent of all cancers …
Dr. Gifford-Jones: Protecting yourself from acute kidney injury – Windsor Star (blog)
Dr. Gifford-Jones: Protecting yourself from acute kidney injuryWindsor Star (blog)A report from Johns Hopkins Hospital says that 20 million Americans suffer from chronic kidney disease. Kidney … According to Karl L. Womer, director of the Transplant …
Gilead Announces Response Data from Phase 2 Study of Idelalisib for … – Fort Mills Times
Gilead Announces Response Data from Phase 2 Study of Idelalisib for …Fort Mills TimesGilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, target…
Gilead Announces Response Data from Phase 2 Study of Idelalisib for … – MarketWatch (press release)
Gilead Announces Response Data from Phase 2 Study of Idelalisib for …MarketWatch (press release)Gilead Sciences, Inc. (NASDAQ:GILD) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigation…
Civic body divided over iconic Mahalaxmi venue – Mumbai Mirror
Civic body divided over iconic Mahalaxmi venueMumbai MirrorThe 99-year lease agreement between the Royal Western India Turf Club (RWITC) and the BMC draws to an end this month, presenting an opportunity to the Shiv Sena, which is scouting for a memoria…
Heart failure patients living longer, but long-term survival still low – HealthCanal.com
|
Heart failure patients living longer, but long-term survival still low
HealthCanal.com BALTIMORE – People hospitalized for acute heart failure are likely to survive longer compared to the prior decade, according to a new study in the Journal of the American Heart Association and presented at the American Heart Association’s Quality of … |
Genentech Cancer Antibody, Son of Rituxan, Nails Pivotal Study – Xconomy
|
Genentech Cancer Antibody, Son of Rituxan, Nails Pivotal Study
Xconomy Genentech has been searching for years to find a way to improve upon rituximab (Rituxan), which set a gold standard 15 years ago as part of the first generation of targeted antibody cancer drugs. Now it looks like Genentech has finally nailed a new and … Roche Experimental Leukemia Drug Helps Shrink TumorsBloomberg Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease …Wall Street Journal (press release) |